Lv1
60 积分 2021-03-03 加入
Orthokeratology for Slowing Myopia Progression in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
12小时前
已完结
The Efficacy of Defocus Incorporated Multiple Segments Lenses in Slowing Myopia Progression
13小时前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
4天前
已完结
HER2-Targeted Therapies: Unraveling Their Role in Biliary Tract Cancers
1个月前
已完结
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial
1个月前
已完结
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study
2个月前
已完结
Recommendations on Perihilar Cholangiocarcinoma. The Milan Jury-Based Consensus
2个月前
已完结
Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)
2个月前
已完结
The Russian consensus on the treatment of intrahepatic cholangiocarcinoma
2个月前
已关闭
Diagnosis and treatment of cholangiocarcinoma in Italy: A Delphi consensus statement
2个月前
已完结
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
5个月前
已采纳
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
5个月前
已采纳
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
5个月前
已采纳
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
5个月前
已采纳
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
5个月前
已采纳
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
5个月前
已采纳
Brain size predicts problem-solving ability in mammalian carnivores
4年前
已采纳
皖公网安备34019202002308
